A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
NCT07543250 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2026-04-21
Summary
A Multicenter, Observational Study on the Real-World Effectiveness and Safety of inavolisib Combined with Endocrine Therapy With or Without a CDK4/6 Inhibitor in Patients with HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer.
Conditions
Interventions
- DRUG
-
Inavolisib in Combination With ET
Inavolisib in Combination With ET
- DRUG
-
Inavolisib in Combination With ET+CDK4/6i
Inavolisib in Combination With ET+CDK4/6i
Sponsors & Collaborators
-
xuliang
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-16
- Primary Completion
- 2026-12-31
- Completion
- 2027-07-30
- FDA Drug
- Yes
More Related Trials
-
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
NCT07441512 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
NCT03006172 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239 ·Status: RECRUITING ·Phase: PHASE3
-
The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment
NCT06810492 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC
NCT07245797 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
NCT06508216 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
NCT02453620 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
NCT07180160 ·Status: RECRUITING ·Phase: PHASE2
-
H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study
NCT05167643 ·Status: UNKNOWN ·Phase: NA
-
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
NCT05295043 ·Status: UNKNOWN ·Phase: NA
-
Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
NCT03153163 ·Status: COMPLETED ·Phase: PHASE1
-
Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
NCT03772353 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
NCT06172322 ·Status: RECRUITING ·Phase: PHASE1
-
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07570966 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
NCT03650894 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
NCT05504213 ·Status: RECRUITING ·Phase: PHASE1
-
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344780 ·Status: ACTIVE_NOT_RECRUITING
-
Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC
NCT07480694 ·Status: NOT_YET_RECRUITING
-
Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
NCT07162259 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT05759546 ·Status: RECRUITING ·Phase: PHASE2
-
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682 ·Status: RECRUITING ·Phase: PHASE2
-
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
NCT07180056 ·Status: RECRUITING
-
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT07018427 ·Status: ACTIVE_NOT_RECRUITING